Redmile Group’s Exact Sciences EXAS Stock Holding History

Redmile Group’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,130	Closed	-$328K	–	82
2018 Q1	$328K	Buy	+8,130	New	+$397K	0.01%	60

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Redmile Group's EXAS Position: Q2 2018 in Review

Redmile Group sold out of Exact Sciences (EXAS) in Q2 2018, closing a stake of 8,130 shares — an estimated $328K sold.

Redmile Group first reported a position in EXAS in Q1 2018 and held it in 1 quarter. The position peaked at $328K in Q1 2018. 348 funds tracked by Wall St. Rank hold EXAS as of Q2 2018.

Redmile Group reported no remaining Exact Sciences position as of Q2 2018 after selling out during the quarter.
Redmile Group sold 8,130 Exact Sciences shares in Q2 2018, an estimated $328K.
Redmile Group first reported a position in Exact Sciences in Q1 2018 and held it in 1 quarter.
Redmile Group's Exact Sciences position peaked at $328K in Q1 2018.
348 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2018.

Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.